Regulation of hematopoietic stem cells and leukemia stem cells by thrombopoietin
血小板生成素对造血干细胞和白血病干细胞的调节
基本信息
- 批准号:9242049
- 负责人:
- 金额:$ 39.6万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-04-01 至 2021-03-31
- 项目状态:已结题
- 来源:
- 关键词:AdultAllelesAlpha CellBcr-Abl tyrosine kinaseBloodBone MarrowBone Marrow CellsCell CycleCell MaintenanceCellsCellular biologyChronic Myeloid LeukemiaClinicalDataDevelopmentDiseaseFrequenciesGene Expression ProfilingGoalsGrowthHematological DiseaseHematopoietic stem cellsHomeostasisHumanImatinibImmune systemKnock-inKnock-outKnowledgeLifeMaintenanceMalignant NeoplasmsMethodsModelingMolecularMusMutationNatureOncogenicOsteoblastsPathway interactionsPhosphotransferasesPropertyRefractoryRegulationRelapseResearchResistanceRoleRosaSourceStem cellsStromal CellsSystemTestingTherapeuticThrombopoietinTyrosineTyrosine Kinase Inhibitorbcr-abl Fusion Proteinscancer stem cellcell typedesignexperimental studyimprovedin vivoinhibitor/antagonistinsightkinase inhibitorleukemialeukemic stem cellmutantnovelnovel therapeuticspublic health relevanceresistance mechanismself-renewaltargeted treatmenttherapeutic targetvon Willebrand Factor
项目摘要
DESCRIPTION (provided by applicant): Hematopoietic stem cells (HSCs) maintain homeostasis of the blood and immune system throughout life. They are tightly regulated by their microenvironmental niche in the bone marrow. Mounting evidence suggests that chronic myeloid leukemia (CML) arise from mutant HSCs. These diseased leukemia stem cells (LSCs) hijack the HSC mechanisms to sustain the cancer growth and cause relapse. Eradication of LSCs is thus pivotal to cure CML. The discovery of the causing active Bcr/abl kinase mutation in CML and the development of tyrosine kinase inhibitors against Bcr/abl have revolutionized the way we treat CML. Tyrosine inhibitors become the first line of treatment against CML. Although tyrosine kinase inhibitors (e.g. imatinib) can manage the disease, they do not eliminate CML-SCs. A major CML-SC resistant mechanism is the protection offered by the bone marrow niche. Elucidating the niche regulatory mechanisms and target the niche protection mechanisms will help eliminate CML-SCs to better treat CML. However, little is known about the LSC niche. The goal of the proposed research is to characterize how thrombopoietin (TPO), an extrinsic factor, regulates HSCs and LSCs. TPO pathway is required for primitive HSC maintenance in mice and humans. It is not known where Tpo-expressing bone marrow cells create a special niche for primitive HSCs. Furthermore it is not known whether TPO pathway is `hijacked' by CML-SCs for their maintenance. Here, we will identify cellular source of TPO in the bone marrow. Then we will test what cells represent functionally important source for HSC maintenance in vivo. Finally, we will functionally test the role of TPO in CML progression with the focus on CML-SCs in vivo. The results of these studies are expected to not only provide new insights on how the bone marrow niche regulates HSC self-renewal and function, but also have the potential to identify therapeutic targets for CML in the niche.
描述(由应用提供):造血干细胞(HSC)一生都保持血液和免疫系统的体内稳态。它们受骨髓中的微环境利基市场的严格调节。越来越多的证据表明,慢性髓样白血病(CML)来自突变的HSC。这些解剖的白血病干细胞(LSC)劫持了HSC机制,以维持癌症的生长并减轻。因此,消除LSC是治愈CML的关键。发现CML中引起活跃的BCR/ABL激酶突变的发现以及针对BCR/ABL的酪氨酸激酶抑制剂的发展彻底改变了我们对待CML的方式。酪氨酸抑制剂成为针对CML的第一道治疗。尽管酪氨酸激酶抑制剂(例如伊马替尼)可以治疗该疾病,但它们不能消除CML-SC。 CML-SC的主要耐药机制是骨髓生态位提供的保护。阐明利基调节机制并针对利基保护机制,将有助于消除CML-SC,以更好地治疗CML。但是,对LSC利基市场知之甚少。拟议的研究的目的是表征血小板蛋白(TPO)如何调节HSC和LSC。 TPO途径是小鼠和人类原始HSC维持所必需的。尚不清楚在哪里表达TPO的骨髓细胞会为原始HSC创建特殊的利基市场。此外,尚不清楚CML-SC是否将TPO途径“劫持”。在这里,我们将确定骨髓中TPO的细胞来源。然后,我们将测试哪些单元在体内代表HSC维护在功能上重要的来源。最后,我们将在功能上测试TPO在CML进程中的作用,重点是体内CML-SC。这些研究的结果不仅有望提供有关骨髓细分市场如何调节HSC自我更新和功能的新见解,而且还具有鉴定利基市场中CML的治疗靶标的潜力。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Lei Ding其他文献
Lei Ding的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Lei Ding', 18)}}的其他基金
Developing Next Generation Genetics for Understanding Hematopoietic Stem Cell Biology
开发下一代遗传学以了解造血干细胞生物学
- 批准号:
10898485 - 财政年份:2022
- 资助金额:
$ 39.6万 - 项目类别:
Developing Next Generation Genetics for Understanding Hematopoietic Stem Cell Biology
开发下一代遗传学以了解造血干细胞生物学
- 批准号:
10710163 - 财政年份:2022
- 资助金额:
$ 39.6万 - 项目类别:
Understanding and targeting bone marrow microenvironment in myelofibrosis
了解和靶向骨髓纤维化中的骨髓微环境
- 批准号:
10543555 - 财政年份:2021
- 资助金额:
$ 39.6万 - 项目类别:
Understanding and targeting bone marrow microenvironment in myelofibrosis
了解和靶向骨髓纤维化中的骨髓微环境
- 批准号:
10321224 - 财政年份:2021
- 资助金额:
$ 39.6万 - 项目类别:
Understanding the role of stellate cells in the liver hematopoietic stem cell niche
了解星状细胞在肝脏造血干细胞生态位中的作用
- 批准号:
10666495 - 财政年份:2020
- 资助金额:
$ 39.6万 - 项目类别:
Understanding the role of stellate cells in the liver hematopoietic stem cell niche
了解星状细胞在肝脏造血干细胞生态位中的作用
- 批准号:
10191033 - 财政年份:2020
- 资助金额:
$ 39.6万 - 项目类别:
Understanding the role of stellate cells in the liver hematopoietic stem cell niche
了解星状细胞在肝脏造血干细胞生态位中的作用
- 批准号:
10449115 - 财政年份:2020
- 资助金额:
$ 39.6万 - 项目类别:
Understanding the role of stellate cells in the liver hematopoietic stem cell niche
了解星状细胞在肝脏造血干细胞生态位中的作用
- 批准号:
10034524 - 财政年份:2020
- 资助金额:
$ 39.6万 - 项目类别:
Regulation of hematopoietic stem cells and leukemia stem cells by thrombopoietin
血小板生成素对造血干细胞和白血病干细胞的调节
- 批准号:
9895854 - 财政年份:2016
- 资助金额:
$ 39.6万 - 项目类别:
相似国自然基金
基于人诱导多能干细胞技术研究突变等位基因特异性敲除治疗1型和2型长QT综合征
- 批准号:82300353
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
PML等位基因突变介导急性早幼粒细胞白血病患者对三氧化二砷耐药的分子机制研究
- 批准号:
- 批准年份:2020
- 资助金额:24 万元
- 项目类别:青年科学基金项目
p38调控CARD9(S12N)杂合子等位基因表达不平衡导致ABPA发生的机制研究
- 批准号:81901673
- 批准年份:2019
- 资助金额:21.0 万元
- 项目类别:青年科学基金项目
等位基因调控TGM6表达介导巨噬细胞极化在抗结核免疫中的作用与机制研究
- 批准号:81970007
- 批准年份:2019
- 资助金额:56 万元
- 项目类别:面上项目
人类基因组中等位基因在父源和母源的基因组中的特异表达和基因印记
- 批准号:81871168
- 批准年份:2018
- 资助金额:57.0 万元
- 项目类别:面上项目
相似海外基金
Investigating the role of CSF production and circulation in aging and Alzheimer's disease
研究脑脊液产生和循环在衰老和阿尔茨海默病中的作用
- 批准号:
10717111 - 财政年份:2023
- 资助金额:
$ 39.6万 - 项目类别:
Identifying new regulators of cardiac fibrosis and inflammation using zebrafish
使用斑马鱼识别心脏纤维化和炎症的新调节因子
- 批准号:
10892436 - 财政年份:2023
- 资助金额:
$ 39.6万 - 项目类别:
Role of SETD5 in Moyamoya Disease Pathogenesis
SETD5 在烟雾病发病机制中的作用
- 批准号:
10724796 - 财政年份:2023
- 资助金额:
$ 39.6万 - 项目类别:
Defining the role of Wnt11 and Wnt5a in regulating hematopoietic and skeletal stem cell self-renewal potential during homeostasis and stress
定义 Wnt11 和 Wnt5a 在稳态和应激过程中调节造血和骨骼干细胞自我更新潜力的作用
- 批准号:
10731650 - 财政年份:2023
- 资助金额:
$ 39.6万 - 项目类别:
Characterization of PDGFR alpha/beta heterodimers
PDGFR α/β 异二聚体的表征
- 批准号:
10676610 - 财政年份:2023
- 资助金额:
$ 39.6万 - 项目类别: